Q-omics provides the consensus-scored NOP56P3 profile across patient tissues and cancer cell-line models. NOP56P3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, NOP56P3 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, NOP56P3 RNA expression shows 10,934 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CHOL, STAD, and LSCC as cancer lineages where NOP56P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOP56P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOP56P3 survival associations across molecular data types. NOP56P3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOP56P3 RNA expression–survival associations across cancer types. High NOP56P3 expression shows unfavorable associations in CHOL, KICH, DLBC and KIRP, but favorable associations in GBM and READ. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CHOL as the clearest survival context for NOP56P3 RNA expression.
This table summarizes NOP56P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for NOP56P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOP56P3 shows higher tumor expression in STAD, LUSC, LIHC, LUAD, ESCA and CHOL. The STAD box plot shows higher NOP56P3 RNA expression in tumor versus normal tissue (log2 FC = +0.479, t-test p < 0.001).
This table shows molecular features associated with NOP56P3 in patient tissues and cancer cell lines. In patient samples, NOP56P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
